GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Immunologic Approaches to Ovarian Cancer

$2,033,832
Paul J Sabbatini · Sloan-Kettering Inst Can Research · P01 · FY2017 · CA

Applying Bioinformatics to Research in Immune, Muscle, and Bone Diseases

$2,033,275
Hong-Wei Sun · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIC · FY2025 · AR

Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule Drugs

$2,032,638
Peter Karl Sorger · Harvard Medical School · U54 · FY2021 · CA

SPORE in Breast Cancer

$2,031,380
Jennifer A Pietenpol · Vanderbilt University Medical Center · P50 · FY2022 · CA

Head and Neck Cancer SPORE at the University of Wisconsin

$2,028,647
Paul M Harari · University Of Wisconsin-Madison · P50 · FY2022 · CA

Strategies for Cancer Immunotherapy Development: Preclinical Studies

$2,028,388
Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA

Molecularly Targeted Radiosensitization of Locally Advanced Cancers

$2,027,150
Theodore S Lawrence · University Of Michigan At Ann Arbor · P50 · FY2025 · CA

MAP4K3 regulation of cellular stress response pathways in health and disease

$2,022,582
Albert R La Spada · University Of California-Irvine · RF1 · FY2022 · AG

Head and Neck Cancer SPORE at the University of Wisconsin

$2,021,133
Paul M Harari · University Of Wisconsin-Madison · P50 · FY2023 · CA

Immunotherapy for Malignant Mesothelioma and Lung Cancer

$2,018,756
Raffit Hassan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Immunologic Approaches to Ovarian Cancer

$2,002,763
Paul J Sabbatini · Sloan-Kettering Inst Can Research · P01 · FY2019 · CA

Integration of Actin Dynamics and Adhesion in Cell Migration

$2,001,484
Clare Michal Waterman · National Heart, Lung, And Blood Institute · ZIA · FY2018 · HL

CNT-VECTORED DELIVERY OF MRNA FOR HIV-VACCINES

$1,999,997
Yang Xu · Luna Innovations, Inc. · N44 · FY2019 · AI

MOONSHOT - TOPIC 372 - DEVELOPMENT AND VALIDATION OF NON-MOUSE REAGENTS TO ENABLE PRECLINICAL DEVELOPMENT OF NOVEL THERAPEUTICS.

$1,999,381
Adriann Sax · Vetigenics Llc · N44 · FY2021 · CA

Vulnerabilities in osteosarcoma and breast cancer

$1,995,196
Jing Huang · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer

$1,993,287
Anil K Sood · University Of Tx Md Anderson Can Ctr · P50 · FY2025 · CA

Centers for Cancer Systems Therapeutics (CaST)

$1,991,851
Andrea Califano · Columbia University Health Sciences · U54 · FY2016 · CA

Centers for Cancer Systems Therapeutics (CaST)

$1,991,657
Andrea Califano · Columbia University Health Sciences · U54 · FY2017 · CA

MD Anderson Cancer Center SPORE in Gastrointestinal Cancer

$1,987,442
Scott Kopetz · University Of Tx Md Anderson Can Ctr · P50 · FY2021 · CA

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs

$1,970,503
Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA

Role of Viral Reservoirs in the Pathogenesis of HIV Disease

$1,963,172
Tae-Wook Chun · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI

Preclinical drug development in pancreatic cancer

$1,962,634
Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Immunological Analysis of Brain Cancer

$1,962,200
Masaki Terabe · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA

SPORE In Prostate Cancer

$1,957,034
William George Nelson · Johns Hopkins University · P50 · FY2012 · CA

Radiopharmaceutical Imaging and Therapy of Cancer

$1,954,858
Peter L. Choyke · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA